SALIX is committed to patient education and care during this time and always. Click here to access helpful resources. REL.0120.USA.20
In a survey* of 441 chronic non-cancer pain (CNCP) patients on opioid therapy with OIC, 64% of patients reported trying OTC medications at the recommendation of their health care provider (HCP)2:
*A national, 1-week online survey sponsored by Salix Pharmaceuticals, in partnership with the US Pain Foundation and conducted by Wakefield Research, which surveyed 441 US adults, aged 18 years or older, who were living with CNCP, on opioid therapy, and suffering from OIC.2
OIC is caused by opioids binding to mu-opioid receptors in the gastrointestinal (GI) tract, significantly slowing GI motility.8,9 Three effects that can contribute to OIC include:
Take a proactive approach to OIC by starting the conversation with your patients. These questions can help to identify OIC:
You are now entering a site that is for US healthcare professionals only. By selecting I Confirm below, you certify that you are a US healthcare professional and wish to proceed to this section of the site. Products or treatments described on this site are available in the United States but may not be available in all other countries.
I certify that I am a licensed US healthcare professional and wish to proceed to the healthcare professional section of this site.
I Confirm Cancel
Thank you for visiting the RELISTOR website; you are now leaving our site. The website you are about to visit is not affiliated with Salix Pharmaceuticals or its affiliated entities, and Salix is not responsible for the content, format, maintenance, or policies of the website you are about to visit. Salix Pharmaceuticals or its affiliated entities do not monitor non-affiliated websites for accuracy. This link does not imply endorsement or support of any programs, products, or services associated with the website.